Locoregional therapies in patients with recurrent intrahepatic cholangiocarcinoma after curative resection

doi:10.1177/1756284820976974

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24287

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24287

Title:	Locoregional therapies in patients with recurrent intrahepatic cholangiocarcinoma after curative resection
Authors:	Liu, HT;Cheng, SB;Lai, CY;Chen, YJ;Su, TC;Wu, CC
Keywords:	Cholangiocaricnoma;hepatectomy;recurrence;prognosis
Date:	2020
Issue Date:	2022-08-09T07:59:49Z (UTC)
Publisher:	SAGE PUBLICATIONS LTD
ISSN:	1756-283X
Abstract:	Background: Hepatectomy is one potential treatment for intrahepatic cholangiocarcinoma (IHCC). Recurrent rate is high after curative resection and most recurrences occur within residual liver parenchyma. The aim of this study was to elucidate the impact of different treatment modalities on recurrent diseases in patients with IHCC after primary liver resection. Methods: Between February 1999 and December 2015, we retrospectively identified patients who received curative resection for IHCC. Patients who experienced recurrences were included. Locoregional therapies included re-hepatectomy, radiofrequent ablation, and transhepatic arterial chemoembolization. These patients were categorized into three groups: intrahepatic recurrence without locoregional therapies (group A), intrahepatic recurrence with locoregional therapies (group B) and extrahepatic metastases (group C). Results: Forty-three patients were included and there were 12, 15, and 16 patients in groups A, B, and C, respectively. The median disease-free survival times were 8.3, 9.1, and 8.7 months in groups A, B, and C (p = 0.099). The median after-recurrence overall survival times (period between recurrence and death/censor) were 6.4, 34.0, and 8.3 months in groups A, B, and C (p = 0.001). Locoregional therapies showed favorable benefit in multivariant analysis (hazard ratio: 0.274, confidence interval: 0.083-0.908, p = 0.010). Conclusion: Locoregional therapies offered favorable benefits for patients with recurrent intrahepatic cholangiocarcinoma.
URI:	http://dx.doi.org/10.1177/1756284820976974 https://www.webofscience.com/wos/woscc/full-record/WOS:000600020000001 https://ir.csmu.edu.tw:8080/handle/310902500/24287
Relation:	THERAPEUTIC ADVANCES IN GASTROENTEROLOGY ,2020 ,v13
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	168	View/Open

Loading...